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BY-NC-ND license (http://creativecomAbstract Objective: To establish a basis for Angelica Sinensis Radix (ASR) as a dietary supple-
ment for colorectal cancer chemoprevention, the effect of co-existent components in super-
critical fluid extract (SFE) of ASR on the pharmacokinetics of Z-ligustilide after oral
administration was investigated in vitro and in vivo.
Methods: Incubation in gastrointestinal contents and incubation in rat liver tissue homoge-
nates post-mitochondrial supernatant (PMS) experiments were used to study changes in the
levels of Z-ligustilide in vitro.
Results: Within 4 hours, the level of Z-ligustilide in SFE declined at a slower rate than in its
pure form. Clearance of Z-ligustilide after administration in its pure form was significantly
slower than that of SFE of ASR (CL, 0.96  0.16 mL$min/kg versus 1.24  0.21 mL$min/kg
P < 0.05; AUC, 243.37  16.84 versus 176.69  12.59 mg$min/L).
Conclusion: These phenomena may be attributed to the interactions between the co-existent
components in SFE of ASR and Z-ligustilide enhancing the stability of Z-ligustilide. These results
suggest that the bioavailability of Z-ligustilide in SFE of ASR is improved. However, stabilization
of plasma concentration was not sustained, so that the efficacy of active components could not
be maintained. Thus, further processing of SFE of ASR is required.
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by-nc-nd/4.0/).0 847 386 03.
(Q. Wu).
f Beijing University of Chinese Medicine.
14.09.007
f Chinese Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
Effect of co-existences on metabolism of Z-ligustilide 127Introduction
The Chinese herb Angelica Sinensis Radix (ASR) is the dry
root of Angelica sinensis (Oliv.) Diels. The Chinese name of
ASR is dang gui (当归), and the herb has been used as a
traditional Chinese medicine for nearly two thousand
years.1 Traditional Chinese medicine theory holds that ASR
promotes blood circulation, tonifies the blood, relieves
pain, and moistens the bowel.2 Modern pharmacologic
research has shown that ASR has anti-coagulation and anti-
inflammation properties.3 In addition to its medicinal use,
ASR is a common ingredient in home cooking in China.
Supercritical fluid extraction (SFE) is a method used to
separate out, or extract, chemical compounds. Supercriti-
cal Fluid Extraction is the process of separating or
extracting the chemical compounds from the matrix using
supercritical fluids as the extracting solvent. Carbon diox-
ide is the most used supercritical fluid, sometimes modified
by co-solvents such as ethanol or methanol. SFE is applied
in several fields, including the petroleum, cosmetic, food,
pharmaceutical, and nutraceutical industries. CO2 at or
above its critical temperature and critical pressure is in the
state of fluid and is known as supercritical CO2. Supercrit-
ical CO2 is a common solvent used in chemical extractions
because of its stability, permeability, and solubility. As
extraction and separation are carried out at a low tem-
perature, decomposition and volatilization of the extracted
compound are prevented. Thus, safety, efficiency, econ-
omy, and environmental protection are the hallmarks of
CO2 supercritical fluid extraction.
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In previous studies, we determined the process param-
eters of CO2 SFE of ASR. Chemical composition of ASR was
characterized by gas chromatography-mass spectrometry.
Based on our research, Z-ligustilide is the most abundant
active component in ASR, reaching a proportion of
42.12%  1.78% (m/m).5
Z-ligustilide was first extracted from Ligusticum acuti-
lobum Siebold & Zucc. by Mitsuhashi in 1960.6 L acutilobum
Siebold & Zucc. is also known as Angelica acutiloba (Siebold
& Zucc.) Kitag, which is in the same genus as Angelica
sinensis (Oliv.) Diels., or ASR. Research on the pharmaco-
logic activities of Z-ligustilide has discovered that it has an
anti-oxidative property and induces vasodilation, thus
improving microcirculation.7 Z-ligustilide has also been
found to activate Nrf-2/ARE-mediated gene expression and
induce anti-inflammatory activities directly through epige-
netic modification.8 We have also reported that SFE of ASR
exhibited colorectal cancer preventive potential in azoxy-
methane/dextran sodium sulfate (AOM/DSS) mice model
through activation of the Nrf-2/ARE pathway. However,
results indicated that even though SFE of ASR could
decrease tumor incidence, high/low-grade intraepithelial
neoplasia was still present at approximately 50%.5,9 Thus,
further investigation is required to assure whether the
route of administration limited the work of Z-ligustilide.
The gastrointestinal tract of animals is a complex envi-
ronment that contains digestive enzymes and microorgan-
isms. This affects the stability and metabolism of drugs in
the digestive tract. Thus, to study the effect of the gastric
and intestinal environment on the metabolism of Z-ligu-
stilide, the gastrointestinal environment was simulated bydissolving the contents of digestive track using artificial
digestion.10 Additionally, as the liver is a major organ of
metabolism, liver tissue homogenate post-mitochondrial
supernatant (PMS) is a rapid and easy technique to study
drug decomposition.11
This study was conducted to compare changes in Z-ligu-
stilide level in gastrointestinal contents and in liver tissue
homogenate PMS in its pure form and SFE of ASR. Pharma-
cokinetics of Z-ligustilide in its pure form and SFE of ASR
were first compared. Interaction between Z-ligustilide and
co-existent components in SFE of ASR were then explored
(Fig. 1).
Materials and methods
Chemicals
Angelica Sinensis Radix was purchased from Ben Cao Fang
Yuan Medical Materials (Beijing, China; No.17643960) and
identified by Professor Chunsheng Liu (Beijing University of
Chinese Medicine). SFE of ASR was extracted as described
previously.5 Z-ligustilide was separated from SFE of ASR by
silica gel column chromatography developed in our labo-
ratory, and reached purity of more than 95%.12
Methanol for high-performance liquid chromatography
(HPLC) was purchased from Fisher Scientific Co. (Shanghai,
China), and internal standard, a-naphthoflavone was pur-
chased from SigmaeAldrich Co. (Shanghai, China). All other
reagents were of analytical grade, and purchased from
Sinopharm Chemical Reagent Co. (Beijing, China).
Experimental animals
Male SpragueeDawley (SD) rats (220  10 g) were supplied
by SPF Experimental Animal Science and Technology Ltd.
(Beijing, China). Animals were housed in the Beijing Uni-
versity of Chinese Medicine Laboratory Animal Department
under standard conditions of temperature, humidity, and
light. Laboratory mice and rats formula feeds and water
were provided ad libitum.
In vitro protocol
Preparation of rat gastrointestinal contents
Male SD rats (n Z 6), that were allowed to fast 12 hours
before the experiment were sacrificed by cervical vertebra
dislocation. The stomach, from cardia to pylorus, was
removed and dissected. Its contents were immersed in 5 mL
artificial gastric juice, and the gastric mucosa was eluted
repeatedly with another 5 mL artificial gastric juice. The
gastric contents were obtained by pooling 10 mL of the
artificial gastric juice.
Intestine, from 10 cm below the pylorus, was sectioned
at 30 cm and dissected. Artificial intestinal juice was
applied with the same manner as gastric content
preparation.
Incubation of ligustilide in gastrointestinal contents
SFE of ASR and Z-ligustilide emulsions were prepared by
first weighing 71.23 mg SFE of ASR and 30.00 mg Z-ligu-
Figure 1 Outline of the article including mainly experimental methods and results.
128 B. Zhao et al.stilide and then adding 1.00% (0.10 g) Tween-80. After
thoroughly blending, 10 mL distilled water was dropped
gradually with stirring.
Ten milliliters gastric or intestinal contents were mixed
with 100 mL SFE or Z-ligustilide emulsion in a beaker, which
was covered by aluminum foil to protect it from light. The
beaker was placed on a thermostatic magnetic stirrer.
Temperature was set to 37C, and stirring speed to 180 rpm.
At 2-h intervals, 100 mL samples were collected. After each
collection, 10 mL internal standard and 190 mL methanol
were added to the sample, which was then vortexed for
1 minute followed by centrifuging at 16 000 g for 10 minutes.
Finally, 10 mL supernatant was harvested for HPLC analysis.
Each group’s experiment was performed in parallel 6 times.
Preparation of rat liver tissue homogenates PMS
Male SD rats (n Z 6) that were allowed to fast 12 hours
before the experiment were sacrificed by cervical vertebra
dislocation. Whole liver was harvested and liver tissue was
weighed, and immersed 4 times in 0.25 mol/L sucrose so-
lution. The liver tissue was homogenized over an ice bath
until there were no visible blocks of tissue. After centri-
fuging at 12 000 g for 15 minutes and removing the sedi-
ment, the liver tissue homogenate post-mitochondrial
supernatant (PMS), containing liver hepatosome and cyto-
plasm, was obtained.13
Incubation of ligustilide in gastrointestinal contents
Ten milliliters liver tissue PMS were mixed with 100 mL SFE
or Z-ligustilide emulsion in a beaker, which was covered by
aluminum foil to protect it from light. The beaker was
placed on a thermostatic magnetic stirrer. Temperature
was set to 37C, and stirring speed to 180 rpm. At 4-h in-
tervals, 100 mL samples were collected. After each collec-
tion, 10 mL internal standard and 190 mL methanol were
added to the sample, which was then vortexed for1 minute, followed by centrifuging at 16 000 g for 10 mi-
nutes. Finally, 10 mL supernatant was harvested for HPLC
analysis. Each group’s experiment was performed in par-
allel 6 times.
In vivo protocol
SD rats (n Z 12) were divided randomly into 2 groups for
oral administration of SFE of ASR emulsion (500 mg/kg body
weight) or Z-ligustilide emulsion (211 mg/kg body weight).
Twelve hours before administration, rats were allowed to
fast but drink ad libitum. Rats were etherized and blood
samples were collected from the orbital sinus using a
heparinized capillary tube with an inside diameter of
1.00 mm. Samples were collected in 1.5 mL heparinized
Eppendorf tubes, and centrifuged at 3 000 g for 10 minutes.
Plasma samples were harvested. Each plasma sample
(100 mL) was mixed with 10 mL internal standard (a-naph-
thoflavone) and 190 mL methanol, vortexed, and centri-
fuged at 15 000 g for 5 minutes. The supernatant was
filtered using a 0.45 mm syringe filter, and 150 mL of the
filtrate was prepared for HPLC analysis. Each group exper-
iment was performed in parallel 6 times.
Quantitative analysis
HPLC method: The HPLC system consisted of a solvent de-
livery unit (LC-20AT; Shimadzu (China) Co., Beijing), a UV/
VIS detector (SPD-20A; Shimadzu), an operating system
software (LCsolution; Shimadzu), and an HPLC small
molecule column (250 mm  4.6 mm, 5 mm) coupled with a
guard column (Grace Alltech Alltima, Beijing, China). The
samples were eluted using a mobile phase at 20:80 water/
methanol, 0.7 mL/min. Z-ligustilide was monitored at a
wavelength of 284 nm.
Figure 2 Changes in levels of Z-ligustilide in gastrointestinal
contents.
(A) Changes in levels of Z-ligustilide in gastric contents; (B)
Changes in levels of Z-ligustilide in intestinal contents. Data
are mean  SD, nZ 6. *P < 0.05, **P < 0.01, comparison made
between SFE group and ligustilide group.
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tion of Z-ligustilide (30 mg/mL) was diluted to the desired
concentrations with methanol. A certain volume of the
diluted solution was spiked into blank plasma from un-
treated SD rats to reach concentrations ranging from 0.25
to 15 mg/L for the in vivo study. The resultant samples
were mixed thoroughly and treated and analyzed in the
same manner as described under the in vivo protocol.
Samples of each concentration were analyzed in triplicate.
Calibration curves were derived by plotting the peak area
ratios of Z-ligustilide to the internal standard as a function
of concentration of Z-ligustilide.
Method validation: Analyses of bio-samples followed Food
and Drug Administration (FDA) guidelines.14 Three concen-
trations of Z-ligustilide at high, medium, and low levels of
the corresponding calibration curves were chosen to be
determined for the intra-day and inter-day variability. The
inter-day variability was determined on 3 separate days over
1 week. Peak area ratio for each concentration was
measured, and concentration of Z-ligustilide was calculated
from the corresponding calibration curve. Precision and ac-
curacy of measures were evaluated by relative standard
deviation and percentage difference between amounts
spiked and determined (absolute recovery), respectively.
The concentration of a sample was at a single-to-noise
ratio or higher than 5 was determined as the limit of
quantitation (LOQ).
Identification of ligustilide in SFE and blood
samples
Ligustilide levels in SFE of ASR and blood samples were
determined using high-performance liquid chromatography
mass spectroscopy (HPLC-MS) (LTQ Orbitrap XL, Thermo
Scientific, Waltham, MA, USA).
Chromatography conditions: Mobile phase consisted of A
(0.25% aqueous acetic acid, v/v) and B (methanol). Gradient
elution was performed as follows: 30% B at 0e10 minutes,
increased linearly to 60% at 20minutes, to 90% at 50minutes,
and to 100% at 70 minutes. Phase A from 0% to 70% was at
80e90minutes andmaintained for 10minutes. Flow ratewas
0.7 mL/min.
Positive electrospray ionization MS was conducted under
the following condition: nebulizing gas, 40 psi; auxiliary
gas, 60 psi; curtain gas, 30 psi; turbo-ion spray tempera-
ture, 400C; declustering potential, 61 V; focusing poten-
tial, 380 V; and ionization potential, 5 500 V. Full scan mass
spectrum was obtained over a range of m/z 50 through 600.
Mass spectrum was recorded with Thermo Scientific Quan-
Lab Forms 2.5 software.
Analysis of pharmacokinetic parameters
Pharmacokinetic parameters were calculated from the
corresponding plasma concentration-time curves using
noncompartmental analysis (WinNonlin 4.1, Pharsight,
Mountain View, CA, USA). Cmax, Tmax, and t1=2 were
measured from the concentration-time profile. Other
pharmacokinetic parameters, including t1=2, AUC0/N,
AUC0/t, CL, and MRT0/N, were calculated using the
following equations:AUC0/NZAUC0/t þClast
lZ
CL=FZDose=AUC0/N
MRTZAUMC0/N=AUC0/N
Vd=FZDose=ðlZ AUC0/NÞ
Where lZ is the terminal rate constant; AUC0/t is the area
under the first moment curve from Time 0 to Time 8.
Statistical analysis
All data and results were expressed as mean  SD. The t
test was applied to compare results between two groups.
Statistical significance was P  0.05.
Results
Changes in levels of ligustilide in gastrointestinal
contents
Levels of Z-ligustilide in its pure form as well as in SFE of
ASR decreased in rat gastrointestinal contents (Fig. 2).
Figure 3 Changes in levels of Z-ligustilide in liver tissue ho-
mogenates PMS.
**P < 0.01, comparison made between SFE group and ligustilide
group.
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19.9% of Z-ligustilide in its pure form were undetectable in
gastric contents. In the intestinal contents, 9.85% of Z-lig-
ustilide in SFE of ASR and 13.85% of Z-ligustilide in its pure
form was undetectable. Significant difference in meta-
bolism of Z-ligustilide between SFE of ASR and its pure formFigure 4 HPLC chromatograms of rat blank plasma (A) and spike
10 mL samples were ejected and eluted using a mobile phase conta
Z-ligustilide was monitored at a wavelength of 284 nm.were not observed, but the decreasing rate of Z-ligustilide
in its pure form was greater than in SFE of ASR. There was
no significant difference in the amounts of degradation of
Z-ligustilide between the gastric and intestinal contents.
Changes in level of ligustilide in liver tissue
homogenates PMS
Within 4 hours, 70.45% and 80.02% of Z-ligustilide were
metabolized in liver tissue PMS in SFE of ASR or in its pure
form, respectively. Within 1.5 hours, 69.81% and 78.80% of
Z-ligustilide (over 98% of metabolic amount), were metab-
olized in SFE of ASR or in its pure form, respectively (Fig. 3).
Method validation
HPLC was considered suitable for the quantification of Z-
ligustilide in samples collected from in vivo studies (Fig. 4).
Z-ligustilide was well separated from its metabolites. Over
the concentration range tested, the calibration curves for
plasma and in vitro samples showed good linearity
(r2 > 0:998). The overall intra-day and inter-day variations
were less than 5% (0.42%e3.15%) (Table 1), and absolute
recovery was higher than 79% (79.15%e84.16%) (Table 2).
These results indicated good reproducibility and precision.
LOQ of Z-ligustilide in rat plasma was 25 ng/L.d with Z-ligustilide and a-naphthoflavone (B).
ins A (80% methanol) and B (20% water) at 0.7 mL/min in HPLC.
Table 1 Accuracy and precision of ligustilide in blood sample preparation (n Z 6, %).
Batch No. 0.25 mg/mL 1 mg/mL 15 mg/mL
Determined conc. Accuracy Determined conc. Accuracy Determined conc. Accuracy
(mg/mL) (%) (mg/mL) (%) (mg/mL) (%)
Batch 1 1 0.25 0.62 1.04 4.39 15.41 2.74
2 0.25 0.31 1.04 4.40 15.48 3.18
3 0.25 1.27 1.05 5.35 15.26 1.71
4 0.26 3.95 1.06 6.45 15.23 1.54
5 0.25 1.18 1.04 4.48 15.23 1.54
6 0.26 2.06 1.05 4.55 15.28 1.87
Mean 0.25 1.05 15.31
SD 0.00 0.01 0.10
RSD (%) 1.98 0.79 0.68
Batch 2 1 0.24 4.19 1.05 5.16 1.06 1.55
2 0.23 6.15 1.04 4.45 1.08 5.63
3 0.25 0.21 1.05 4.60 1.06 6.94
4 0.24 5.96 1.05 4.90 1.07 4.02
5 0.24 2.15 1.05 4.98 1.07 1.16
6 0.25 0.54 1.06 5.70 1.06 5.15
Mean 0.24 1.05 1.07
SD 0.01 0.00 0.01
RSD (%) 2.71 0.42 2.22
Batch 3 1 0.24 0.04 1.06 5.67 15.36 2.43
2 0.24 0.11 1.08 7.88 15.41 2.71
3 0.24 0.08 1.06 6.05 15.45 2.98
4 0.25 0.11 1.07 7.32 15.25 1.65
5 0.24 0.08 1.07 7.19 15.30 1.99
6 0.24 0.10 1.06 6.25 15.15 0.99
Mean 0.24 1.07 15.32
SD 0.00 0.01 0.11
RSD (%) 1.37 0.80 0.72
Inter-Batch Mean 0.24 1.06 15.41
SD 0.01 0.01 0.25
RSD (%) 3.15 1.05 1.62
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Peak of Ligustilide was found using HPLC/MS analysis
(Fig. 5). In Fig. 5, protonated molecular ion ([MþH]þ) was
at m/z 191 peak, deethylation molecular ion was at m/z
161 peak, and depropylation molecular ion was at m/z 145
peak. Decarbonylation and break of lacton bond would
produce the ion peak at m/z 134, m/z 121, m/z 106, and
m/z 91 respectively. Peak at m/z 78 was from the molec-
ular fragment of benzene. Chromatogram retention time of
ligustilide was 39.56 minutes and NL was 3.92E7. Lysis
started from the side chain, two collision cleavage path-
ways were butenyl losing and breaking of lactone bond with
dehydration and decarbonylation (Fig. 6).
Pharmacokinetic study
Plasma concentration-time curves of Z-ligustilide after oral
administration in its pure form or SFE of ASR were plotted
(Fig. 7). Pharmacokinetic parameters were calculated and
summarized (Table 3). The plasma concentrateetime pro-
file and pharmacokinetic parameters could be obtained,
only if the dose of SFE of ASR and Z-ligustilideadministrated reached 500 mg/kg bodyweight and 211 mg/
kg bodyweight. At doses of 100 mg/kg and 300 mg/kg, most
response values of plasma samples were lower than LOQ, or
even could not be detected. After oral administration, Z-
ligustilide exhibited extensive distribution in the body (Vd,
339.53  65.37 and 240.92  76.12 L/kg) and rapid elimi-
nation (t1=2, 182.46  79.78 and 199.82  74.46) in its pure
form or SFE of ASR, respectively. Z-ligustilide was absorbed
rapidly (Tmax; 19.20  15.26 and 17.43  11.40 min)
reaching a Cmax of 1.71  0.27 and 1.32  0.12. Within
3 hours, concentration of Z-ligustilide declined to 0.5 ng/L,
a level which was maintained for the next 5 hours. Reten-
tion of Z-ligustilide (MRT, 258.64  78.76 and
299.27  114.6) reflects the long-lasting terminal phase.
The value of total body clearance (CL) of Z-ligustilide in its
pure form was significantly higher than that of in SFE of ASR
(1.24  0.21 versus 0.96  0.16).
Discussion
A large number of drugs or active components have been
studied for their chemo-preventive effect in experimental
animals, and some of these drugs have even been applied
Table 2 Recovery of ligustilide in blood samples (n Z 6,
%).
Group Concentration (mg/mL) x  SD RSD%
Low 0.2 79.15  4.99 4.99
Middle 1 84.16  1.65 1.65
High 15 80.25  1.69 2.11
132 B. Zhao et al.clinically.15 Chemopreventive agents can be divided into 2
types, synthetic agents and natural substances. Selective
estrogen receptor modulators (SERMs), non-steroidal anti-
inflammatory drugs (NSAID), and oral antidiabetic drug
metformin are representative drugs of synthetic agents.16Figure 5 HPLC chromatograms and Mass spectra of ligustilidePolyphenols from green tea,17 curcumin from ginger,18
sulforaphane from broccoli,19 resveratrol from grape and
wine,20 and Z-ligustilide from angelica are also well studied
as chemopreventive natural products. Long-term and con-
stant usage has shown these vegetables, spices, and bev-
erages are safe and reliable for human administration.
From the results of this study, the gastrointestinal sur-
roundings, including pH, bioactive enzyme, and gastroin-
testinal microorganism, are not the notable factor
influencing stability or metabolism of Z-ligustilide either in
its pure form or in SFE of ASR. In spite of that, the 8 hours
metabolism rate and decreasing rate of Z-ligustilide in its
pure form were greater than in SFE of ASR. The interpre-
tation for this phenomenon is that the co-existent compo-
nents in SFE of ASR enhance the stability of Z-ligustilide.in its pure form (A), blood sample (B), and SFE of ASR (C).
Figure 6 A proposed lysis pathway of Ligustilide in the rat.
Lysis was started from the side chain, two collision cleavage pathway were butenyl losing and breaking of lactone bone with
dehydroation and decarbonylation.
Figure 7 Mean plasma concentration-time profiles of Z-lig-
ustilide in rat after oral administration.
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ously, isomerization of Z-ligustilide and clathration or
covered up by co-existent components were inferred to be
sound explanation for the improvement of Z-ligustilide
stability in gastrointestinal contents.
Results from liver tissue homogenates PMS experiments
indicated that Z-ligustilide regardless of in its pure form or
in SFE of ASR was eliminated rapidly in the first 90 minutes.
As for the ceasing reaction after 90 minutes, a rationalTable 3 Pharmacokinetic parameters of Z-ligustilide after
oral administration (n Z 6).
Pharmacokinetic
Parameter
SFE
(0.5 mg/mL)
Z-Ligustilide
(0.211 mg/mL)
Tmax (min) 19.20  15.26 17.43  11.40
Cmax (mg/L） 1.71  0.27* 1.32  0.12
t1=2 (min) 182.46  79.78 199.82  74.46
Vd=F (L/kg） 339.53  65.37* 240.92  76.12
AUC0/N (min$mg/L) 293.43  44.26* 228.28  42.00
AUC0/t (min$mg/L） 243.37  16.84* 176.69  12.59
CL (mL/min/kg) 0.96  0.16* 1.24  0.21
MRT0/N (min） 258.64  78.76* 299.27  114.36
Note: *P < 0.05 comparison made between SFE group and lig-
ustilide group.explanation was that the lack of NADPH-regenerating sys-
tem blocks the bio-redox cycle, so once the substrate
exhausted, the reaction was forced into discontinuation.
The overall trend of Z-ligustilide elimination was fully re-
flected within 1.5 hours liver tissue PMS metabolic experi-
ments, and the conclusion of liver being the main metabolic
organ for Z-ligustilide can be validated.
Pharmacokinetic study indicated that ligustilide was
absorbed apace (Tmax; 17:43 11:40 min) and eliminatedFigure 8 Main metabolites of ligustilide in rat.
Gly: glycine; Cys: cysteine; Glu: glutamate.
134 B. Zhao et al.rapidly (t1=2; 199:82 74:46 min). The clearance of Z-ligu-
stilide after administration in its pure form was significantly
lower than that dose in SFE of ASR (CL, 0.96  0.16
mL$ min/kg versus 1.24  0.21 mL$min/kg (P < 0.05); AUC,
243.37  16.84 versus 176.69  12.59 mg$min/L). Com-
bined with the results of metabolism study in liver tissue
homogenates PMS and in gastrointestinal contents, the
conclusion could be obtained that the extensive first pass
metabolism in liver is one of the reasons of low oral
bioavailability of Z-ligustilide.
From the results of this study, the stability of Z-ligu-
stilide was improved in SFE of ASR in gastrointestinal con-
tents. Metabolic rate of Z-ligustilide in SFE of ASR after oral
administration showed greater AUC on concentration-time
profiles than in its pure form. The reason may be that the
co-existent components in SFE improved the stability of Z-
ligustilide and moderated the pharmacokinetic
characteristics.
Ligustilide is metabolized mostly through aromatization,
hydration, oxidation, and glultathione conjugation
(Fig. 8).21 Further research is needed to explore the specific
interaction between Z-ligustilide and the co-existent com-
ponents in SFE of ASR. Aspects that we intend to look into
include the conclusion effect of co-existent components to
Z-ligustilide and isomerization equilibrium of Z-ligustilide
and its isomer such as butylidenephthalide. In addition,
though the stability of Z-ligustilide was improved, its serum
concentration during a certain time period was still not
maintained. Therefore, further pharmaceutic processing is
also warranted in the development of SFE of ASR for che-
moprevention of colorectal cancer. Using a new delivery
system to change the route of administration and devel-
oping sustained and controlled release preparations are
possible solutions to avoid the first-pass effect and improve
bioavailability.Acknowledgments
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